Genetic control couples TGF β -independent pluripotent stem cell renewal to deterministic forward programming across germ layers
Authors:
- Sveva BottiniSBSveva Bottini
- Francesca AmodeoFAFrancesca Amodeo
- Mario De GregorioMGMario De Gregorio
- Maddalena ArigoniMAMaddalena Arigoni
- Fabian BachingerFBFabian Bachinger
- Philip BarrettPBPhilip Barrett
- David L. MackDMDavid L. Mack
- Paolo E. PorporatoPaolo E. Porporato
- Paola DefilippiPaola Defilippi
- Ludovic VallierLVLudovic Vallier
- Alec S. T. SmithASAlec S. T. Smith
Preprint
Abstract
Reproducible and scalable manufacture of human induced pluripotent stem cell (hiPSC) derivatives requires control over expansion and differentiation. Transcription factor-mediated forward programming can place hiPSC differentiation under genetic control, but expansion still relies on extracellular growth-factor supplementation, increasing process complexity and operator dependence. Here we introduce GERALT ( G enetically E nhanced R enewal and A utonomous L ineage T ransdifferentiation), a push–pull genetic circuit assembled through targeted safe-harbour integration that couples NANOG-supported, TGF β -independent renewal to doxycycline-inducible lineage programming and simultaneous NANOG silencing. GERALT maintained pluripotency during extended TGF β withdrawal in both adherent and suspension culture, yet remained programmable towards myogenic, neuronal, and hepatic fates. Compared with the established OPTi-OX platform in myogenesis, GERALT enabled differentiation in simplified medium while canalising and accelerating commitment. GERALT also supported direct myogenic programming in suspension and enabled direct casting of hiPSCs into hydrogel followed by in-tissue programming, yielding electrically responsive engineered muscle tissues. These results extend genetic control upstream into stem cell renewal, facilitating deployment of new approach methodologies and other biomanufacturing applications.Keywords
Funding Information
- National Center for Gene Therapy and Drugs based on RNA Technology (CN00000041)
This publication has 56 references indexed in Scilit:
- New approach methodologies for drug discoveryCell, 2026
- Two decades of induced pluripotent stem cell research: From discovery to diverse applicationsCell Stem Cell, 2026
- Scaling up pluripotent stem cell-based therapies - considerations, current challenges and emerging technologies: perspectives from the ISCT Emerging Regenerative Medicine Working GroupCytotherapy, 2025
- Elucidation of the pluripotent potential of bovine embryonic lineages facilitates the establishment of formative stem cell linesCellular and Molecular Life Sciences, 2024
- Unlocking the potential of cultivated meat through cell line engineeringiScience, 2024
- Suppression of toxic transgene expression by optimized artificial miRNAs increases AAV vector yields in HEK-293 cellsMolecular Therapy - Methods & Clinical Development, 2024
- Human pluripotent stem cell‐derived products: Advances towards robust, scalable and cost‐effective manufacturing strategiesBiotechnology Journal, 2014
- An Optimized microRNA Backbone for Effective Single-Copy RNAiCell Reports, 2013
- Rapid Single-Step Induction of Functional Neurons from Human Pluripotent Stem CellsNeuron, 2013
- Differentiation of Embryonic Stem Cells to Clinically Relevant Populations: Lessons from Embryonic DevelopmentCell, 2008